In Brief: Wyeth-Ayerst's Cordarone IV
Executive Summary
Wyeth-Ayerst's Cordarone IV: Injectable formulation of the antiarrhythmic amiodarone is "approvable" again on April 24. Cordarone IV was previously "approvable" on Feb. 10 ("The Pink Sheet" Feb. 27, In Brief). The company subsequently submitted amendments to the NDA and may be discussing manufacturing issues with FDA...